Fagron Genomics provides personalized, science-based treatment recommendations specifically for Aesthetics, Dermatology, Trichology, and Nutrition. The company specializes in the development and servicing of medical genetic algorithms.

Fagron Genomics

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.

Linda Avey

Paul Cusenza

Anne Wojcicki

23andMe Holding Co.

Ancestry.com LLC is an American genealogy company based in Lehi, Utah. It is the largest for-profit genealogy company in the world, operating a network of genealogical, historical records, and related genetic genealogy websites. The company provides access to billions of historical records and has sold millions of DNA kits to customers.

Metric
Company Name	Fagron Genomics	23	Ancestry.com LLC
Symbol		ME
MSH ID	COM:FAGRONGENOMICS	COM:23ANDME	COM:ANCESTRY
Market	PRIVATE	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Technology
Industry	Genetics and Biotechnology	Medical - Diagnostics & Research	Genealogy, genetic genealogy, online publishing, software publishing
Country	ES	US	US
Stage
Employee Count		560	1.84K
Website	fagrongenomics.com	23andme.com	ancestry.com
LinkedIn		23andme	ancestry.com
Founders

Metric
Market Cap		225.52M
Enterprise Value
Monthly Web Traffic		6.55M
Web Traffic Growth		-0.06
Valuation
Raised Capital

Metric
Revenue		219.64M
Revenue (LTM)
Revenue (NTM)
Gross Profit		99.38M
EBITDA		-291.88M
Operating Income		-321.36M
Net Income		-666.70M
EPS		-1.40
Diluted EPS		-1.40
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.45
Operating Profit Margin		-2.17
EBITDA Margin		-1.33
Net Profit Margin		-2.10
Return on Equity		-0.87
Return on Assets		-0.86
Return on Capital Employed		-1.16

COM:FAGRONGENOMICS

Fagron Genomics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-0.93
P/B Ratio		0.50
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		13.37
EV Multiple		-3.85

Metric
Days Sales Outstanding		2.03
Days Payables Outstanding		21.21
Days Inventory Outstanding		48.94
Operating Cycle		97.37
Cash Conversion Cycle		62.09
Asset Turnover		0.56

Metric
Operating Cash Flow		-155.53M
Free Cash Flow		-165.19M
Cash Flow to Debt		-1.75
Operating Cash Flow/Sales		-0.65
Free Cash Flow Yield		-0.50

Metric
Cash & Equivalents		217.89M
Accounts Receivable		-1.43M
Inventory		12.46M
Goodwill
Debt to Capitalization		0.34
Debt to Assets		0.10
Current Ratio		2.93
Quick Ratio		1.87

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.49
R&D to Revenue		0.87
SG&A to Revenue		0.53